Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 575 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

OPKO Health to take over Cytochroma

Under the purchase, OPKO intends to include Cytochroma’s Replidea and Alpharen, which are in Phase 3 clinical trials with kidney disease patients, into its product portfolio. Vitamin D

MorphoSys divests AbD Serotec to Bio-Rad

Transfer of all assets and liabilities of MorphoSys’ research and diagnostic antibody segment, the AbD Serotec, in addition to all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys

CoDa NEXAGON demonstrates efficacy in Phase 2b study

The results of vehicle-controlled, double-blind, randomised Phase 2b study support the advancement of Nexagon into Phase 3 registration trials. The UNC Limb Salvage/Wound Healing Center medical director and